Sol Barer, PhD
|Dr. Barer is a biotechnology industry veteran, and the founder and former Chairman, President, COO and CEO of Celgene, a Nasdaq-Listed Company (NASD: CELG). He brings to InspireMD over 30 years of experience with publicly traded biotechnology companies. In 1980, when Dr. Barer was with Celanese Research Company, he formed the biotechnology group that was subsequently spun out to form Celgene. Dr. Barer spent 18 years leading Celgene as President, COO and CEO, culminating with his tenure as Celgene’s Executive Chairman and Chairman before retiring in June of 2011. Celgene’s market capitalization at his retirement was approximately $27 billion.
Dr. Barer is a Director of Amicus Therapeutics, Inc., Aegerion Pharmaceuticals, Inc. and ContraFect Corp. and serves as a senior advisor to a number of other biotechnology companies. Dr. Barer also serves as Chairman of the Board of Trustees of the Biotechnology Council of New Jersey and is on the Board of Trustees of Rutgers University, the Brooklyn College Foundation and the Tourette Syndrome Association. Dr. Barer was previously the Commissioner of the New Jersey Commission on Science and Technology. Dr. Barer holds a Ph.D. in organic chemistry from Rutgers University and a bachelor’s degree from Brooklyn College.
James J. Barry, PhD
|James J. Barry, Ph.D., is executive vice president and chief operating officer of Arsenal Medical. Prior to Arsenal Medical, Dr. Barry held a variety of senior positions at Boston Scientific, most recently senior vice president of Corporate Technology Development where he oversaw corporate R&D and preclinical science. While at Boston Scientific, Dr. Barry initiated and led the company’s drug-eluting stent programs. Under Dr. Barry’s leadership, the TAXUS™ drug-eluting coronary stent was developed and became the most successful medical device ever launched, attaining annual sales exceeding $3 billion. Prior to joining Boston Scientific, Dr. Barry held positions at Howmedica and Kontron Instruments. Dr. Barry is the author of multiple articles in peer reviewed publications and holds more than 35 U.S. patents. He currently serves on the advisory boards of the Massachusetts Life Sciences Center, University of Massachusetts-Lowell College of Sciences and Yale University’s College of Biomedical Engineering. Dr. Barry holds a doctorate in biochemistry from the University of Massachusetts-Lowell and a Bachelor of Arts in chemistry from Saint Anselm College.|
Michael Berman, MBA
|Michael Berman is a successful entrepreneur within the medical device industry. He joined Scimed in 1986, leading its marketing activities until its merger with Boston Scientific in 1995. From 1995-2000 he served as President of Boston Scientific/Scimed where he provided leadership and management for more than 4000 employees in four locations, and in 1997 he was named a member of Boston Scientific’s Executive Committee. Since leaving Boston Scientific, Mr. Berman co-founded or was a founding director of seven medical technology companies, a number of which have been acquired by leading strategic medical device companies. He currently serves on the board of eight medical industry companies; Aetherworks, Apnex, Benechill, Cardiosonic, PharmaCentra, MikrobEX, AngioSlide and InterValve. Mr. Berman received both his BS and MBA at Cornell University and was inducted into the Minnesota Business Hall of Fame in 2010.|
|Mr. Loughlin was named to the Board of Directors in September of 2012 and serves as Chairman of the Audit Committee. Mr. Loughlin, an experienced corporate director, served as the National Director of the Pharmaceuticals Practice at KPMG, including a five-year term as member of the Board of Directors of KPMG, LLP. Additionally, Mr. Loughlin served as Chairman of the Pension and Investment Committee of the KPMG Board from 1995 through 2001. He also served as Partner in charge of Human Resources, Chairman of the Personnel and Professional Development Committee, Secretary and Trustee of the Peat Marwick Foundation and a member of the Pension, Operating and Strategic Planning Committees. Mr. Loughlin also serves on the boards of Celgene Corp. and Edge Therapeutics, Inc.|
Mr. Milinazzo brings more than two and a half decades of executive management experience in the life sciences sector. He spent 12 years as an executive with Boston Scientific Corporation in numerous executive roles, including Vice President of Marketing for SCIMED Europe. Mr. Milinazzo then served as Vice President of Medtronic Inc.’s Vascular business, as well as, Vice President and General Manager of Medtronic’s Coronary and Peripheral businesses. He was instrumental in the development and commercialization of a number of key products while at Medtronic, including the company’s first drug coated stent platform, Endeavor, which has generated over $1 billion in revenues since its launch. Most recently, Mr. Milinazzo served at Orthofix International in 2005 as Chief Operating Officer and succeeded to the position of CEO in April of 2006.
Mr. Milinazzo currently serves as a director of Flexion Therapeutics, Medpace and Trimedics and holds a bachelor’s degree, Cum Laude, from Boston College.
Dr. Campbell Rogers
|Dr. Rogers currently serves as the Chief Medical Officer of HeartFlow, Inc., a private cardiovascular diagnostics company based in California. Prior to joining HeartFlow, Dr. Rogers was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, a Johnson & Johnson company. Before Cordis, he was an Associate Professor of Medicine and Director of the Cardiac Catheterization Laboratory at Harvard Medical School, Brigham and Women’s Hospital in Boston.|
|Paul S. Stuka is a Managing Member of Osiris Partners and a 30-year investment industry veteran. Prior to forming Osiris Partners, Mr. Stuka was a Managing Director of Longwood Partners, managing small cap institutional accounts. In 1995, Mr. Stuka joined State Street Research and Management as manager of its Market Neutral and Mid Cap Growth Funds. From 1986 to 1994, Mr. Stuka served as the general partner of Stuka Associates, where he managed a U.S.-based investment partnership. Mr. Stuka began his career in 1980 as an analyst at Fidelity Management and Research. As an analyst, Mr. Stuka followed a wide array of industries including healthcare, energy, transportation, and lodging & gaming. Early in his career he became the assistant portfolio manager for three Fidelity Funds, including the Select Healthcare Fund, which was recognized as the top performing fund in the U.S. for the five-year period ending December 31, 1985. In 1984 he became the original manager of the Fidelity OTC Fund, which was the second-best performing U.S. mutual fund for 1985, appreciating 69%. At the time of his departure in June, 1986, the Fund had appreciated over 115% in 18 months and assets approached $1 billion. During his career, Mr. Stuka has been featured in articles in The Wall Street Journal, Barron’s, The New York Times, and BusinessWeek.|